$LIXT

Lixte Biotechnology Holdings Inc

  • NASDAQ
  • Biotechnology
  • Health Technology

PRICE

$2.367 ▲0.017%

Extented Hours

VOLUME

5,141

DAY RANGE

2.3501 - 2.3666

52 WEEK

0.472 - 9.5

Join Discuss about LIXT with like-minded investors

profile
@singletary #StockTraders.NET
recently

I'll take more breaks more often so they stocks just go to zero $lixt $veru

127 Replies 6 👍 15 🔥

profile
@Math #StockTraders.NET
recently

$LIXT offering

98 Replies 15 👍 15 🔥

profile
@Chano #StockTraders.NET
recently

$LIXT too expensive locate

142 Replies 10 👍 6 🔥

WI
@WINTERTRADE #StockTraders.NET
recently

$LIXT nice

106 Replies 12 👍 10 🔥

profile
@singletary #StockTraders.NET
recently

$lixt 6m candle there on squeeze

146 Replies 14 👍 12 🔥

profile
@Chano #StockTraders.NET
recently

$LIXT is due for a raise following chronology of their offerings, last time they had an ATM, it's a 1 day wonder player

121 Replies 10 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

watchlist short: $BTCS, $lIXT, $ATHE, $AACG,

120 Replies 15 👍 14 🔥

profile
@maletone #StockTraders.NET
recently

$LIXT hold up please

92 Replies 11 👍 10 🔥

profile
@maletone #StockTraders.NET
recently

hopefully $lixt gives us an opportunity tomorrow

61 Replies 10 👍 10 🔥

profile
@maletone #StockTraders.NET
recently

I hope they keep $LIXT up for tomorrow so we can reshort it

46 Replies 7 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

covering some more $LIXT under 2.10

81 Replies 14 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

$LIXT doing it too

63 Replies 7 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

will start covering some $LIXT

128 Replies 8 👍 13 🔥

profile
@singletary #StockTraders.NET
recently

$lixt nice pull

142 Replies 11 👍 14 🔥

profile
@maletone #StockTraders.NET
recently

$SENS & $LIXT lower

94 Replies 6 👍 10 🔥

profile
@maletone #StockTraders.NET
recently

would be nice if $LIXT really trapped but doesnt feel like it will

43 Replies 11 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

$LIXT might break .50

128 Replies 9 👍 10 🔥

profile
@nepestheone #StockTraders.NET
recently

1/5/2022 [9:07 AM] LIXT- similar to NLSP yest i expect crowd then a possible short opp later using 3.50-5 res. If you want to long dips imo 2.40-2.20 support 5 min trend [9:07 AM] MYNZ- watching for a potential pump and short using 20.50-23 resistance they may try to squeezeout first paytience bc blue sky breakout assume 18-17 support from prior run [9:07 AM] RELI- ideally one more retest of 9.50 zone for sub 8 targets

129 Replies 8 👍 9 🔥

profile
@maletone #StockTraders.NET
recently

$LIXT feels like it has a bigger float than 4.5 mill

111 Replies 13 👍 8 🔥

profile
@CarlosH-carvan #ivtrades
recently

$LIXT booom

65 Replies 9 👍 8 🔥

SO
@soheil.n #StockTraders.NET
recently

no borrows for me..closest VWAPBLVD is at 3..38 which is based on the 17 m vol day > @maletone said: I'm watching $LIXT

89 Replies 6 👍 12 🔥

BR
@brAli #StockTraders.NET
recently

$lixt im looking to join 3.25 to 3.8

74 Replies 8 👍 15 🔥

profile
@maletone #StockTraders.NET
recently

I'm watching $LIXT

53 Replies 6 👍 7 🔥

Key Metrics

Market Cap

5.22 M

Beta

-0.31

Avg. Volume

13.69 K

Shares Outstanding

2.25 M

Yield

0%

Public Float

0

Next Earnings Date

Next Dividend Date

Company Information

lixte biotechnology holdings, inc. (lixte) is a clinical-stage public (lixt) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. the current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and dna damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. the phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. the lead compound lb-100 is in phase i trial and has the potential to be first-in-class. the deacetylase in

Website:

HQ: ,

Related News